Search

Aim: The situation, structure, and facilities of hospitals change in a crisis, which negatively affects the provision of care quality of health services. One of the current world crises is the Covid-19 pandemic. This study aimed to investigate the preparedness of hospitals to deal with the Covid-19 crisis. Materials and Methods: This narrative review searched the SID, PubMed, Scopus, Google Scholar databases/search engines in published articles between 2019-2022. A search strategy was defined for PubMed and it was translated into other selected databases. Also, the reference list of the included articles was searched. The databases/search engines were searched by two authors independently, and any disagreement was resolved through discussions. To find related articles, Iranian and International databases were searched using Persian keywords and their English equivalents (Covid-19, Hospital, Preparedness, epidemic, and Pandemic). Results: A total of 311 articles were found, of which 15 were reviewed. Inclusion criteria included being an original paper, in Persian or English, and compliance with the purpose of the study. The exclusion criteria included not having access to the full text of the article. The study showed that hospital preparedness against the Covid-19 pandemic in most countries and different regions in Iran is not optimal. Hospitals should be prepared in terms of personal protective equipment, staffing, and beds. Rapid response management and hospital equipment should be strengthened. Conclusion: Considering the desirability of patient preparation in coping with Covid-19, it is necessary to improve healthcare facilities by increasing the number of workforce and beds. [ABSTRACT FROM AUTHOR]

Background: Evidence indicates the protective role of Irisin on nervous tissue following ischemic events, by preventing the cascades of secondary damage. We conducted this scoping review to summarize what has been discovered so far on the neuroprotective effects of Irisin, with a focus on ischemic stroke. Methods: Search strategies were designed based on the keywords related to ischemic stroke and Irisin. Next, an extensive search in Medline, Embase, Scopus, and Web of Science was conducted by the end of April 2022. Two researchers independently reviewed the articles and performed the screening of the selected papers according to the inclusion criteria. Finally, the required data were extracted to a checklist designed based on the PRISMA guideline. The "meta" package was used for the meta-analysis, and heterogeneity between studies was assessed using the I2 test. Results: Pooled data analysis showed that the Irisin administration significantly improved the neurological function following cerebral ischemia / reperfusion injuries (SMD = 3.08; 95% CI: 1.10, 5.06; p<0.0001). Additionally, meta-regression demonstrated that the improvement in neurological function was directly related to the dose of administered Irisin (meta-regression coefficient = 0.03; p = 0.02). Moreover, Irisin administration significantly reduced the volume of infarcted lesions (SMD= -3.14; 95% CI: -4.23, -2.04; p<0.0001), the amount of edema in the brain (SMD= -2.30; 95% CI: -4.07, -0.53; p<0.0001), and the extend of neuronal-cell apoptosis rate (SMD= -4.67; 95% CI: -8.15, -1.19; p<0.0001). Conclusion: The present study demonstrates that the administration of Irisin in animal models of cerebral ischemia / reperfusion injuries is associated with a significant dose-dependent improvement in neurological function. Due to the limited number of articles, more research on the aim of finding the optimum Irisin dosage is in high demand. [ABSTRACT FROM AUTHOR]